Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Bladder Cancer: Update Bulletin [November 2017]

Product Code:
596200936
Publication Date:
November 2017
Format:
PDF
Price:
£910

This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: EU approvals of two PD-1/PD-L1 checkpoint inhibitors Roche’s Tecentriq (atezolizumab) and Merck & Co.’s Keytruda (pembrolizumab) as monotherapies for certain patients with locally advanced or metastatic bladder cancer; Spectrum Pharmaceuticals’ initiation of a new Phase III study of Qapzola (apaziquone) in patients with low- and intermediate-risk non-muscle invasive bladder cancer (NMIBC); the first detailed results from Eli Lilly’s RANGE study with Cyramza (ramucirumab) presented at the annual European Society for Medical Oncology (ESMO) congress in September 2017.

Business Questions:

• Are Tecentriq and Keytruda expected to disrupt treatment patterns in bladder cancer?
• Which of the two PD-1/PD-L1 inhibitors do KOLs favour, and why?
• What other settings do experts expect PD-1/PD-L1 inhibitors to be used in the treatment of bladder cancer?
• For Qapzola’s latest Phase III trial to be deemed successful, what types of recurrence and response rates will KOLs want to see?
• If approved, will the market tolerate a high price for Qapzola?
• Is Cyramza-plus-docetaxel’s improvement in progression-free survival in metastatic bladder cancer sufficient to enthuse the KOLs?
• How important will overall survival data be for Cyramza’s success in bladder cancer? What will KOLs benchmark this against?
• If approved, where in the treatment pathway is Cyramza likely to fit?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved